The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index; 2 of the 14 sources its claims cite were checked for support.
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
Open accessAbstract
BACKGROUND GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials. METHODS For this meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials that included at least 500 participants with type 2 diabetes, compared a GLP-1 receptor agonist with placebo with at least 12 months of follow-up, and reported a primary clinical kidney or cardiovascular outcome, from database inception to March 26, 2024. Post hoc, we included the SELECT trial (NCT03574597), which enrolled participants with cardiovascular disease and a BMI of 27 kg/m2 or more without diabetes. Study-level summary data were extracted independently by two authors for inclusion in this random-effects analysis. The main kidney outcome was a composite outcome, consisting of kidney failure (kidney replacement therapy or a persistent estimated glomerular filtration rate [eGFR] <15 mL/min per 1·73 m2), a sustained reduction in eGFR by at least 50% or the nearest equivalent, or death from kidney failure. The main cardiovascular outcome was MACE, consisting of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This study is registered with PROSPERO, CRD42024528864. FINDINGS Of the 5140 records identified through the literature search, 11 trials, involving 85 373 participants (29 386 female, 55 987 male), were included in the meta-analysis. In participants with type 2 diabetes (67 769), GLP-1 receptor agonists reduced the composite kidney outcome by 18% compared with placebo (hazard ratio [HR] 0·82, 95% CI 0·73-0·93; I2 =26·41%), kidney failure by 16% (HR 0·84, 0·72-0·99; I2 =0%), MACE by 13% (HR 0·87, 0·81-0·93; I2 =49·75%), and all-cause death by 12% (HR 0·88, 0·83-0·93; I2 =0%). The effect on the composite kidney outcome (HR 0·81, 95% CI 0·72-0·92; I2 =23·11%), kidney failure (HR 0·84, 0·72-0·98; I2 =0%), MACE (HR 0·86, 0·80-0·92; I2 =48·9%), and all-cause death (HR 0·87, 0·82-0·91; I2 =0%) was similar when the SELECT trial was included, with no evidence of heterogeneity between this trial and those including participants with type 2 diabetes (pheterogeneity >0·05). There was no difference in the risk of serious adverse events, including acute pancreatitis and severe hypoglycaemia, between the GLP-1 receptor agonist and placebo groups (risk ratio [RR] 0·95, 95% CI 0·90-1·01; I2 =88·5%). However, treatment discontinuation due to adverse events occurred more frequently in the GLP-1 receptor agonist groups (RR 1·51, 95% CI 1·18-1·94; I2 =96·3%). INTERPRETATION We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events. FUNDING None.
Overview
CoChat Summary
TL;DR
This meta-analysis of 11 randomized trials and 85,373 participants found that GLP-1 receptor agonists reduced clinically important kidney outcomes, kidney failure, MACE, and all-cause death in people with type 2 diabetes, with consistent effects when the SELECT trial in people without diabetes was included. Benefits were accompanied by no significant increase in key adverse events, though treatment discontinuation due to adverse events was more frequent with GLP-1 receptor agonists.
Key findings
- In participants with type 2 diabetes, GLP-1 receptor agonists reduced the composite kidney outcome by 18% (HR 0.82, 95% CI 0.73–0.93; high-certainty evidence), kidney failure by 16% (HR 0.84, 95% CI 0.72–0.99; moderate-certainty evidence), MACE by 13% (HR 0.87, 95% CI 0.81–0.93; high-certainty evidence), and all-cause death by 12% (HR 0.88, 95% CI 0.83–0.93; high-certainty evidence).
- When the SELECT trial was included, effects were similar: composite kidney outcome HR 0.81 (95% CI 0.72–0.92), kidney failure HR 0.84 (95% CI 0.72–0.98), MACE HR 0.86 (95% CI 0.80–0.92), and all-cause death HR 0.87 (95% CI 0.82–0.91), with no evidence of heterogeneity by diabetes status (all p-heterogeneity >0.05).
- GLP-1 receptor agonists also reduced worsening kidney function (HR 0.79, 95% CI 0.68–0.92 in type 2 diabetes; HR 0.78, 95% CI 0.68–0.91 including SELECT) and hospitalisation for heart failure by 13%, with no significant heterogeneity by diabetes status (p=0.48).
- There was no statistically significant difference in total serious adverse events (31.7% vs 32.9%; RR 0.95, 95% CI 0.90–1.01), but treatment discontinuation due to adverse events was more frequent with GLP-1 receptor agonists (12.7% vs 9.2%; RR 1.51, 95% CI 1.18–1.94); rates of acute pancreatitis, severe hypoglycaemia, pancreatic cancer, medullary thyroid cancer, and retinopathy were similar.
Methods
- Systematic review and meta-analysis of aggregate data from randomized controlled trials, reported per PRISMA and prospectively registered (PROSPERO CRD42024528864).
- MEDLINE, Embase, and Cochrane CENTRAL were searched to 26 March 2024 for trials with at least 500 participants with type 2 diabetes, GLP-1 receptor agonist versus placebo, at least 12 months of follow-up, and a primary clinical kidney or cardiovascular outcome; the SELECT trial was added post hoc. Eleven trials involving 85,373 participants were included (67,769 with type 2 diabetes and 17,604 without diabetes).
- Random-effects inverse-variance meta-analysis of hazard ratios or log relative risks, with heterogeneity assessed by I², leave-one-out analyses, trial-level subgroup analyses, number needed to treat, and GRADE certainty assessment.
Limitations
- The paper states that kidney outcome definitions were not uniform across trials; kidney failure event rates were low in all trials except FLOW; and kidney disease outcome was not the primary outcome in all trials except FLOW.
- The paper states that lack of individual participant-level data prevented subgroup analyses by participant-level baseline characteristics (e.g., presence or type of heart failure), and that SELECT was the only trial enrolling participants without diabetes, limiting subgroup analyses by diabetes status; all included trials were industry-funded.
- The paper notes high heterogeneity for total serious adverse events (I²=88.5%) and treatment discontinuation due to adverse events (I²=96.3%), so those summary statistics should be interpreted carefully; this is a limitation evident from the reported heterogeneity.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 1 Not valid · 8 Not checked · 80 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A previous meta-analysis showed a 21% relative risk reduction in a different composite kidney outcome, mainly driven by new-onset macroalbuminuria. 22”
What the sources say
- Partly supportedcites [22] Sattar, 2021, Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials, Lancet Diabetes Endocrinol sourceExperimental — accuracy not yet measured
The Abstract reports a 21% reduction in the broad kidney composite (HR 0.79), and the Fig. 4 caption confirms that this outcome includes new-onset macroalbuminuria and differs from the narrower kidney-function outcome. Our copy does not establish that new-onset macroalbuminuria mainly drove the reduction. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“all-cause death by 12% (HR 0·88, 95% CI 0·83 to 0·93, I 2 =0%)”
- Also stated in: § Cardiovascular Outcomes · boosted
“Compared with placebo, treatment with GLP-1 receptor agonists resulted in a 12% relative reduction in the risk of death due to any cause in participants with type 2 diabetes (HR 0·88, 95% CI 0·83 to 0·93; high-certainty evidence)”
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Cardiovascular Outcomes · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with no evidence of heterogeneity between this trial and those including participants with type 2 diabetes (all p-heterogeneity >0·05)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MACE by 13% (HR 0·87, 95% CI 0·81 to 0·93, I 2 =49·75%)”
- Also stated in: § Cardiovascular Outcomes · boosted
“Compared with placebo, treatment with GLP-1 receptor agonists resulted in a 13% reduction in the risk of MACE (HR 0·87, 95% CI 0·81 to 0·93; high-certainty evidence) in participants with type 2 diabetes”
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Cardiovascular Outcomes · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“nonfatal stroke by 13% (HR 0·87, 95% CI 0·79 to 0·96; Figure 2D)”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
44 more claims
Create a free account to see all 91 claims and to verify the 12 references still open.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 14
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent meta-analysis confirmed little heterogeneity in terms of outcomes in the FLOW trial and in the relevant CVOTs (16).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Implicit bias remains a central concern, influencing clinical judgment in ways that may lead to underestimation of cardiometabolic risk or assumptions about medication adherence, particularly among racial and ethnic minority and socioeconomically disadvantaged patients. Such biases can result in fewer discussions about, and lower rates of initiation of, advanced cardiometabolic therapies [23].”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the treatment of type 2 diabetes and obesity, offering substantial benefits in glycaemic control, weight reduction, and cardiovascular outcomes.”
From Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis (2025) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“943/43309 (2.5%)”
Reported 2.5 · recomputed 2.177377
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Added value of this study
“Treatment effects for all outcomes appeared consistent regardless of diabetes status.”
§ Cardiovascular Outcomes
“Significant heterogeneity in treatment effect was observed for nonfatal myocardial infarction (HR 0·87, 95% CI 0·79 to 0·97; p-heterogeneity=0·02)”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Self-citationThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Self-citation
Research works printed but not linked: 3
- 2024, Volume 1: chronic kidney disease, Am J Kidney Dis, 83, S1
- 2024, Volume 2: end stage renal disease, Am J Kidney Dis, 83, S256
- Schünemann, 2023, Chapter 14. Completing ‘Summary of findings’ tables and grading the certainty of the evidence
Cited by
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501006 · Cited by 416
Self-citationRafferty, Q., Stafford, L. K., Vos, T., Thomé, F. S., Aalruz, H., Abate, Y. H., Abbafati, C., ElHafeez, S. A., Abedi, A., Abiodun, O. O., et al. (2025) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00198-6 · Cited by 214
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationGLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J. M., Guo, Y. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2681 · Cited by 124
Herrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 150
Metadata
- Authors
- Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., Mann, J. F. E., Colhoun, H. M., Tuttle, K. R., Pratley, R. E., & Perkovic, V.
- Affiliations
- UNSW Sydney (AU)
- AdventHealth Orlando (US)
- University of Glasgow (GB)
- Population Health Research Institute (CA)
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- University of Chicago (US)
- Stanford Medicine (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Institute of Genetics and Cancer (GB)
- University of Washington (US)
- Corresponding author
- Badve, Sunil V
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2025-01
- Volume
- 13
- Issue
- 1
- Pages
- 15-28
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4404685978
- Semantic Scholar
- 976f8e7244a381e653779b0508b853d79bd140df
- Cited by
- 359
- References
- 48
- Citations by year
- 2026: 207 · 2025: 151
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.gla.ac.uk
- Licence
- cc-by-sa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, renal failure, major adverse cardiovascular events, cardiovascular disease, estimated glomerular filtration rate, renal replacement therapy, cardiovascular mortality, myocardial infarction, stroke, renal protection, cardioprotection, SELECT trial, placebo comparison, drug safety and efficacy, drug discontinuation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. https://app.cochat.ai/papers/10.1016/s2213-8587(24)00271-7
- The paper
- Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., Mann, J. F. E., Colhoun, H. M., Tuttle, K. R., Pratley, R. E., & Perkovic, V. (2025). Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00271-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.